drugset / Trial / NCT05382819
A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis
Phase 1
Terminated
89 enrolled
Fresh Tracks Therapeutics, Inc.
Innovaderm Research Inc. · collabSyneos Health · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
FRTX-02 is an orally-available, potent and selective DYRK1A inhibitor.
Timeline
- Start
- 2022-05-16
- Primary completion
- 2023-02-08
- Completion
- 2023-08-11
Outcome
Outcome not reported
Stopped (Business): “Business Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FRTX-02 | Unknown | — | Oral |